carbetocin + oxytocin

The entry **b-Shahid Beheshti University of Medical Sciences-postpartum hemorrhage** refers to a clinical research context, specifically a Phase 2 trial conducted by Shahid Beheshti University of Medical Sciences, comparing the efficacy of **carbetocin** and **oxytocin** for the prevention of postpartum hemorrhage (PPH) in women undergoing cesarean section. Carbetocin is a synthetic, long-acting analogue of the peptide hormone oxytocin. Both agents act as agonists at the oxytocin receptor (OXTR) in the uterine myometrium, stimulating contractions that compress intra-myometrial blood vessels to reduce blood loss after delivery. While oxytocin is the standard of care typically administered as a continuous intravenous infusion, carbetocin is designed with a longer half-life, allowing for a single-dose administration. The trial evaluates whether carbetocin's pharmacokinetic profile offers superior clinical outcomes or improved convenience in the management of PPH compared to standard oxytocin protocols.

Brand names

PabalDuratocinPitocinSyntocinon

Other names

OxytocinCarbetocin